Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...
Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...
A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson's disease (PD) motor symptoms during all waking hours for patients with ...
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...
Hoogma RPLM et al. (2005) Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: ...
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...
The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...
Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. A ...
The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes. The Food and Drug ...
The potential value of continuous monitoring of blood glucose and the enzyme-based electrode that underlies continuous glucose monitoring (CGM) in the subcutaneous tissue were described in the 1960s.
The effect of switching from multiple daily insulin injections to an insulin pump on insulin and other diabetic drug expenditures in type 2 diabetes. Continuous users of MDI therapy throughout the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results